title: Increased systemic exposure to rhizoma coptidis alkaloids in lipopolysaccharide-pretreated rats attributable to enhanced intestinal absorption.
abstract: Rhizoma coptidis is a rhizome commonly used in traditional Chinese medicine. After oral administration of rhizoma coptidis extract, the plasma concentrations of its effective alkaloid constituents are so low that their systemic therapeutic actions cannot be explained. This study aimed to investigate the influence of lipopolysaccharide (LPS) on the pharmacokinetics of the rhizoma coptidis alkaloids. Pharmacokinetic experiments were performed with rats; both in vitro absorption and efflux experiments were carried out with everted rat gut sacs, whereas in vitro metabolism experiments were conducted with rat liver microsomes and intestinal S9 fractions. Mucosal changes were evaluated with light microscopy and transmission electron microscopy. The results showed that, in rat plasma, LPS pretreatment increased systemic alkaloid exposure. LPS pretreatment increased the in vitro absorption of the alkaloids and decreased their efflux. The efflux of vinblastine and rhodamine 123, P-glycoprotein substrates, also was decreased. The absorption of fluorescein isothiocyanate-labeled dextran (average molecular mass, 4 kDa), a gut paracellular permeability probe, was not influenced. Obvious damage was observed in the mucosa, but the tight junctions between epithelial cells remained intact. Intestinal, rather than hepatic, alkaloid metabolism was decreased. These findings indicated that LPS pretreatment increased systemic exposure to the alkaloids through enhancement of their absorption, which was related to decreased intestinal efflux and metabolism. The results add to the understanding of why rhizoma coptidis is active despite the low plasma concentrations of the rhizoma coptidis alkaloids measured in normal subjects and experimental animals.
authors.affiliation: Department of Pharmacology, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China.
authors.forename: Bing-Liang
authors.initials: BL
authors.lastname: Ma
authors.forename: Meng-Kan
authors.initials: MK
authors.lastname: Yao
authors.forename: Jie
authors.initials: J
authors.lastname: Zhong
authors.forename: Yue-Ming
authors.initials: YM
authors.lastname: Ma
authors.forename: Cheng-Lu
authors.initials: CL
authors.lastname: Gao
authors.forename: Jia-Sheng
authors.initials: JS
authors.lastname: Wu
authors.forename: Fu-Rong
authors.initials: FR
authors.lastname: Qiu
authors.forename: Chang-Hong
authors.initials: CH
authors.lastname: Wang
authors.forename: Xin-Hong
authors.initials: XH
authors.lastname: Wang
mesh_terms: D000470:Alkaloids / Q000097:blood / Q000737:chemistry / Q000378:metabolism / Q000493:pharmacokinetics*; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000493:pharmacokinetics*; D001599:Berberine / Q000031:analogs & derivatives / Q000032:analysis / Q000097:blood / Q000737:chemistry / Q000378:metabolism / Q000493:pharmacokinetics; D001682:Biological Availability; D000089042:Coptis chinensis; D004365:Drugs, Chinese Herbal / Q000737:chemistry / Q000493:pharmacokinetics*; D005260:Female; D020719:Glucuronides / Q000378:metabolism; D007082:Ileum / Q000276:immunology / Q000378:metabolism* / Q000648:ultrastructure; D007249:Inflammation / Q000097:blood / Q000378:metabolism* / Q000473:pathology; D007408:Intestinal Absorption; D007413:Intestinal Mucosa / Q000276:immunology / Q000378:metabolism* / Q000648:ultrastructure; D008070:Lipopolysaccharides; D008297:Male; D008862:Microsomes, Liver / Q000378:metabolism; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley
chemical_list: D000470:Alkaloids; D000894:Anti-Inflammatory Agents, Non-Steroidal; D004365:Drugs, Chinese Herbal; D020719:Glucuronides; D008070:Lipopolysaccharides; D001599:Berberine; C477155:demethyleneberberine; C107393:Coptidis rhizoma extract